E-ISSN: 2314-7326
P-ISSN: 2314-7334

Journal of Neuroinfectious Diseases
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Cerebrospinal Fluid Neopterin and CXCL13 are Suitable Biomarkers for Staging and Detection of Treatment Failure in a Non-Human Primate Model of Human African Trypanosomiasis

Dawn N Maranga1*, Maina J Ngotho3, Victor M Mwadime2, Thomas A Adino2, John Kagira1,5, Maxwell Waema6, George A Omondi2, Sylvain Biéler4 and Joseph M Ndungu4

1Tropical and Infectious Diseases Department, Institute of Primate Research, Kenya

2Animal Sciences Department, Institute of Primate Research, Kenya

3Department of Animal Health and Production, Mount Kenya University, Kenya

4Foundation for Innovative New Diagnostics, Switzerland

5Department of Land Resources Planning Management, Jomo Kenyatta University of Agriculture and Technology, Kenya

6Department of Public Health, Jomo Kenyatta University of Agriculture and Technology, Kenya

*Corresponding Author:
Dawn N Maranga
Tropical and Infectious Diseases Department, Institute of Primate Research
P.O. Box 24481-00502 Karen, Nairobi, Kenya
Tel: +25420884308
E-mail: dawn.maranga@gmail.com

Received Date: March 17, 2017; Accepted Date: May 09, 2017; Published Date: May 12, 2017

Citation: Maranga DN, Ngotho MJ, Mwadime VM, Adino TA, Kagira J, et al. (2017) Cerebrospinal Fluid Neopterin and CXCL13 are Suitable Biomarkers for Staging and Detection of Treatment Failure in a Non-Human Primate Model of Human African Trypanosomiasis. J Neuroinfect Dis 8:246. doi: 10.4172/2314-7326.1000246

Copyright: © 2017 Maranga DN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Abstract

Background: Follow-up of treated human African trypanosomiasis (HAT) patients has been a routine practice for confirming cure and early detection of treatment failure.

Objective: The aim of this study was to verify whether the neopterin and CXCL13 biomarkers are suitable for determining the stage of disease, and for monitoring the efficacy of treatment in a vervet monkey model of HAT.

Methods: Six monkeys were infected with Trypanosoma brucei. Late stage disease was induced by sub-curative treatment with diminazene aceturate (DA) from 28 days’ post-infection (dpi). When relapses occurred, the animals were treated curatively with melarsoprol (Mel B) from 82 dpi. Blood and cerebrospinal fluid (CSF) samples were collected at weekly intervals and assessed for parasitosis, as well as tested for neopterin and CXCL13 by ELISA, for a period of 39 weeks.

Results: The concentration of neopterin in serum increased rapidly after infection in early disease (stage 1), peaking at 14 dpi. Levels then dropped rapidly to pre-infection levels by 35 dpi. In contrast, there was a marginal increase in CSF neopterin during early infection, with a minor peak at 21 dpi. Serum CXCL13 increased rapidly from 7 dpi, peaking at 28 dpi, after which the levels dropped upon sub-curative treatment with DA. The concentration of CXCL13 in CSF also increased gradually in early stage disease and continued to rise after sub-curative treatment with DA. Curative treatment with Mel B resulted in its gradual decline, reaching pre-infection levels 105 days later.

Conclusions: The changes in CSF neopterin and CXCL13 correspond to important time-points and stages of the disease. That peak levels coincided with time of relapses demonstrates the potential of these biomarkers in staging and detecting treatment failure. Moreover, the rapid fall in CSF neopterin after curative treatment confirms its great potential for use in development of a test of cure.

Keywords

Top